Should This Patient Start a Statin?
Combine Framingham, SCORE2, or QRISK3 with prednisone dose and carotid plaque overrides, or read our SCORE2 vs. QRISK3 calibration guide.
Systemic synovitis accounts for 30.4% of excess cardiovascular events unseen by general-population lipid scores. Recalibrate Framingham, ASCVD, or SCORE2 baseline output with EULAR weighting, prednisone hazard, and carotid plaque rules.
EULAR 1.5x calibration shifts baseline 6.0% to 9.0% (intermediate band). Up to 42% of reclassified RA patients harbor silent carotid plaque.
Uncorrected Framingham and ACC/AHA Pooled Cohort Equations underpredict 28% to 34% of observed 10-year cardiovascular events in rheumatoid arthritis because active inflammation suppresses LDL cholesterol while accelerating arterial plaque. Sources: Crowson et al., Ann Rheum Dis 2018 and Crowson et al., PLOS ONE 2017.
| Population Equation | Observed / Predicted | RA Multiplier | Impact on Statin Eligibility |
|---|---|---|---|
| Framingham Risk Score | Underpredicts 34% | 1.0x (Uncorrected) | Delays primary lipid therapy when DAS28 > 3.2 |
| ACC/AHA Pooled Cohort | Underpredicts 28% | None native | Requires manual inflammatory risk-enhancer override |
| QRISK3 (RA Weighted) | Calibrated 1.04 | Built-in RA hazard | Captures RA diagnosis and steroid exposure directly |
| EULAR + ATACC-RA Rule | Target 0.98 | 1.5x (Universal RA) | Reclassifies 11% of borderline cases into treat tier |
Observed ATACC-RA cardiovascular events diverge above Framingham predictions from Year 3 onward when active synovitis persists.
Combine Framingham, SCORE2, or QRISK3 with prednisone dose and carotid plaque overrides, or read our SCORE2 vs. QRISK3 calibration guide.
Simulate how CRP suppression under MTX, TNFi, and tocilizumab reverses inflammation-driven hypolipidemia.
Screen ORAL Surveillance age and smoking red flags and compare vascular hazard ratios across csDMARDs and biologics.
Evaluate B-mode carotid duplex and Agatston calcium thresholds alongside preserved consortium citations.